PolyPid Shares Fall on Abdominal-Surgery-Treatment-Trial Results

Shares of PolyPid Ltd. dropped on Friday morning after the company said the Phase 3 study for its treatment D-PLEX(100) did not achieve its primary endpoint in reducing surgical-site infections for abdominal-surgery patients.